Inhibitor treatment: State of the art

Disease-a-Month

Volumn 49, Issue 1, 2003, Pages 22-38

  Shapiro, Amy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; BLEEDING; BOLUS INJECTION; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLANZMANN DISEASE; HALF LIFE TIME; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; REVIEW; SURGICAL PATIENT;

EID: 0037246119     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(03)90012-5     Document Type: Review

References (37)

1. Baudo F, Redaelli R, Caimi TM, et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000;99:21-24.
2. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996;26(suppl 1):135-138.
3. Chuansumrit A, Isarangkura P, Angchaisuksiri P, et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia 2000;6:61-65.
4. Cooper HA, Jones CP, Campion E, et al. Successful use of high dose rFVIIa in a high titre inhibitor patient with haemophilia B during major orthopaedic manipulations and rehabilitation to release fixed flexion contractions of both knees. Haemophilia 2000;6(abstr 45):297-298.
5. d'Oiron R, Ménart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000;83:644-647.
6. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis 1991;21:1-4.
7. Grossmann RE, Geisen U, Schwender S, et al. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrands disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83:633-634.
8. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993;7:78-83.
9. Hedner U, Kristensen H, Berntorp E, et al. Pharmacokinetics of rFVIIa in children. Haemophilia 1998;4:355.
10. Jiménez-Yuste V, Villar A, Foncillas MA, et al. Are higher doses needed of recombinant activated factor VII in haemophiliac paediatric patients with inhibitor? Haemophilia 2000;6(abstr):298.
11. Jiménez-Yuste V, Villar A, Morado M, et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Hemophilia 2000;6:588-590.
12. Kenet G, Lubetsky A, Gitel S, et al. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII. Blood Coag Fibrinol 2000:11:S35-S38.
13. Kenet G, Lubetzky A, Luboshitz J, et al. Treatment of inhibitor patients with rFVIIa: Continuous infusion protocols as compared to a single, large, dose. Haemophilia 2000;76(abstr 44):297.
14. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
15. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.
16. Lorenzo JI, Montoro JM, Aznar JA. Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. Haemophilia 1999;5:135-138.
17. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol 1998;63:7-10.
18. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: Management. Semin Thromb Hemost 2000;26:179-188.
19. Lusher JM, Ingerslev J, Roberts HR, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinol 1998;9:119-128.
20. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. RFVIIa Study Group. Haemophilia 1998;4:790-798.
21. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998;53:249-255.
22. McPherson J, Sutcharitchan P, Lloyd J, et al. Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region. Blood Coagul Fibrinol 2000;11(suppl 1):S31-S34.
23. Ménart C, Cognet V, Petit PY, et al. Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of NovoSeven. Blood Coagul Fibrinol 1998;9:289-290.
24. Montoro JB, Altisent C, Pico M, et al. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia 1998;4:762-765.
25. Rocino A, Miraglia E, Ziello L, et al. Successful continuous infusion (CI) rFVIIa treatment during surgery in two high responding inhibitor patients with hemophilia A. Haemophilia 1998;4(abstr):350.
26. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999;104:22-26.
27. Santagostino E, Rocino A, Gringeri A, et al. Continuous infusion of recombinant activated factor VIIa (rFVIIa) for treatment of high titre inhibitor patients: The Italian experience. Haemophilia 2000;6(abstr 43):279.
28. Saxon BR, Jory CB. Effective prophylaxis with daily rFVIIa (NovoSeven) in a child with high titre inhibitors and a target joint. Haemophilia 2000;6(abstr 49):299.
29. Scaraggi FA, De Mitrio V, Marino R, et al. Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: Advantages of administration by continuous infusion over bolus intermittent injections. Blood Coagul Fibrinol 1999;10:33-38.
30. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 1998;4:564-567.
31. Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996;75:432-436.
32. Schulman S, d'Oiron R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinol 1998;9(suppl 1):S97-S101.
33. Schulman S, rFVIIa-CI Group. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000;26:421-424.
34. Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/mL is associated with an increased incidence of bleeding. Thromb Haemost 2001;86:949-953.
35. Stieltjes N, Ounnoughene N, Vassilieff D, et al. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Haemost 1997;50(suppl, abstr):PS-202.
36. Tagariello G, de Biasi E, Gajo GB, et al. Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: Experience of two cases. Haemophilia 2000;6:581-583.
37. Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery. Eur J Haematol 1998;63(suppl):15-17.